Peer Review History
| Original SubmissionFebruary 12, 2020 |
|---|
|
PONE-D-20-04093 Process evaluation of enhancing primary health care for non-communicable disease management: uncovered the fidelity & feasibility elements PLOS ONE Dear Dr. LOW, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please see the comments below. Please submit your revised manuscript by Aug 30 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Fernando C. Wehrmeister Academic Editor PLOS ONE Additional Editor Comments: The manuscript addressed an important research question, especially in a middle income setting. As pointed out by the reviewers, the methods section needs to be improved for a better understanding of the study. Also, improvements in discussion is needed. Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (i) whether consent was informed and (ii) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.” 3. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. 4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ 6. Please include a separate caption for each figure in your manuscript. 7. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript attempts to address an important question by evaluating a primary healthcare initiative to improve NCD care management in Malaysia. The findings are rich and informative, but need to be presented in a more intelligible fashion. The manuscript as it currently stands has potential but lacks rigor and detail, and needs major revisions. Specifically: 1. It is unclear how utilization was defined and assessed. 2. How were the 20 public primary health care centers sampled/identified? The authors do not describe this. 3. The authors mention that data collection was conducted 2 months vs 3-5 months after the program was implemented, but do not mention how these two different data collection time points may have impacted the results. Given that 2 months of implementation is very short, implementation differences may have been observed between clinics that had data collection at 2 months vs 5 months? 4. Were the IDIs unstructured? semi-structured? This should be described in the methods. Additionally, authors should include the data collection instrument as an appendix to the manuscript if possible. 5. Authors do not explain the rationale for selecting only 1 participant per clinic. Additionally, the participants varied in terms of their role/responsibility in the clinic, therefore the breadth of implementation components evaluated (fidelity, feasibility, adaptation, benefit) could have been different from one clinic to another depending on the participant's level of exposure/role. This should be mentioned as a potential limitation, given there was only 1 participant per clinic. 6. There is insufficient detail to describe how much the checklist changed between the two iterations. 7. Figure 1 is not very informative and does not add to the manuscript. Its findings should be covered in the results section text. 8. The results section is somewhat difficult to follow, and authors have combined background/context elements, evidence from other studies (which needs to be moved to the discussion section) and results from this particular study. The results section needs restructuring. It should also clearly summarize the key implementation components being evaluated (fidelity, feasibility, adaptation, benefit). 9. It would be informative to tell the reader how much is "some clinics", "few clinics", in the results. Perhaps add a proportion, so that the reader can assess how common some challenges were across the 20 clinics. 10. The discussion section needs to be strengthened to clearly summarize the key findings in terms of fidelity, feasibility, adaptation and benefit of the program being evaluated, and to put them into context with other studies/programs, etc. 11. Authors should also state key recommendations based on their findings. 12. Careful grammar editing is needed throughout the manuscript. Reviewer #2: NCDs are relevant and increasing public health issues in low- and middle-income countries, but often neglected as priority for health interventions or health research issues. The paper is interesting and reads well. However, please see below a few comments aiming to improve it. Title: Geographic area to include in the title (e.g. “…..in two states in Malaysia”). Background: Lines 49 to 61 in the background seem more appropriate as methods points, and preferable to move to the methods section, namely the study design and sampling. Methods: Study design and sampling The description of the study design needs to be developed. You can move in that section a few methods aspects developed in the background as per comment above. The sampling section seems a bit weak and needs to be deeply improved. It was indicated that the intervention was implemented in 40 public health care clinics (20 control clinics and 20 intervention clinics) at two selected states. Do the 20 PHC of the evaluation only include the 20 intervention clinics or both intervention and control clinics? In the event, both type of clinics are included, can you explicit the process for sample size calculation and whether you assessed the precision and power of the sample to be able to detect significant difference between intervention and control clinics? In the event the 20 clinics for the evaluation are intervention clinics only, can you explain the rationale of focusing on the intervention clinics only as you may have missed a good opportunity to shape an interesting and relevant design comparing intervention and control clinics? Additionally whether you focus on the intervention clinics, can you provide an explanation with respect to the choice of the two states for the intervention and try to discuss how they may (or not) be representative of the overall national situation as the assessment aims to end up to evidences that may help for scaling up the intervention? Results: The quality of figures on the PDF format seems poor and needs to be improved. Moreover, the figures need to be numbered properly and well referenced in the text, and figures titles need to be clear and more explicit with respect to the information presented. For statements like “The current availability of human resource for health in Malaysia is still low when compared to OECD countries” (page 10), it would be good to provide ratios or estimates whether available. Whether feasible and data available, it would be desirable to have more results. For instance, it may be interesting to know to which extent the secondary triage may have helped improving the detection of undiagnosed NCD cases for ensuring care continuity (lines 186-187). From the PHC register, are there collected data with respect to the patients that may be used for diagnosis and patient case classification? In the same vein, when you say that longer patient waiting time was observed in clinics with insufficient personnel to perform tasks at secondary triage counter (lines 190-191), it will be worthwhile trying to quantity the ‘longer patient waiting time’; or quantitative information in tracing appointment defaulter (line 234) and patients’ adherence to appointments (line 250); or estimating NCD screening activities performed properly according to main reference document for NCD screening (line 259; 265, 266, 270, 271)), or to which extent the referral system was improved (line 311), etc. Discussions: It would be desirable to shape the discussions section as per the evaluation-focused four dimensions i.e. fidelity, feasibility, adaptation and benefit. Concerning the design and dimensions of the evaluation, it makes sense and it is relevant as you assessed the ‘structural quality’ of the intervention (staff, infrastructure, structure, organization, etc.), but it may have also been worthwhile trying to address the process quality for such an intervention (e.g. appropriate triage/assessment of NCDs patients health, appropriate examination of patients, and appropriate diagnosis, or appropriate treatment, referral and counseling, etc.) as that would have been relevant for such an evaluation with the aim to scale-up the intervention package. You may have made the choice to focus on the ‘structural quality’, but good to justify more that choice in the discussions as well as the choice why the design did not address the process quality of care. It may also be relevant to discuss the scale-up opportunity and challenges with respect to scaling up such interventions in other regions or nationwide. Format: Review the text and double-check typo issues (e.g. line 74 “being introduce”, line 234 “Some clinic has initiated by creating their own”, etc.) ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-04093R1 Process evaluation of enhancing primary health care for non-communicable disease management in Malaysia: uncovering the fidelity & feasibility elements PLOS ONE Dear Dr. LOW, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 04 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Fernando C. Wehrmeister Academic Editor PLOS ONE Additional Editor Comments (if provided): The manuscript had improved. However, minor details should be addressed. Please see the reviewer comments. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Thanks to the authors for addressing the comments. It was a good idea to describe the intervention components using a box (Box 1). However, you provided too much detail, so the box is on two pages. Ideally, we expect an embedded box to be one page as an embedded figure. Therefore, it will be nice to cut down a bit and fit on one page. As per the comments, you tried to describe further the sampling process (Page 6-7, line 30-39). However, the place (Background) you inserted this description does not seem appropriate. In the methods, there is a section titled “Study design and sampling”, but there is no information regarding the sampling in that section. I suggest that you move the description of the sampling process (Page 6-7, line 30-39) from the background to the section “Study design and sampling”. There was also a comment regarding the sample size. Since you have excluded the control clinic, there was no longer a need to address the comment related to the power of the sample to detect significant difference between the intervention and control clinics. However, the comment remains relevant concerning the precision of the sample. It is evident that a sample of 20 clinics and 20 health workers seems small and would not provide a good sample precision. It may therefore be worth addressing that issue (small sample size) as a limitation of the study. Concerning the discussions, you made considerable efforts to reshape this section and provided valuable additional information. Otherwise, the authors have well addressed the remaining comments. Best wishes. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Abdoulaye Maïga, PhD [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Process evaluation of enhancing primary health care for non-communicable disease management in Malaysia: uncovering the fidelity & feasibility elements PONE-D-20-04093R2 Dear Dr. LOW, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Fernando C. Wehrmeister Academic Editor PLOS ONE Additional Editor Comments (optional): The paper had improved since its first version. Congratulations to the authors for the excellent job done. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-04093R2 Process evaluation of enhancing primary health care for non-communicable disease management in Malaysia: uncovering the fidelity & feasibility elements Dear Dr. LOW: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Fernando C. Wehrmeister Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .